11β-Hydroxysteroid dehydrogenase-1 is involved in bile acid homeostasis by modulating fatty acid transport protein-5 in the liver of mice

Molecular Metabolism

Volumn 3, Issue 5, 2014, Pages 554-564

  Penno, Carlos A ^a   Morgan, Stuart A ^b   Rose, Adam J ^c   Herzig, Stephan ^c   Lavery, Gareth G ^b   Odermatt, Alex ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

11 Hydroxysteroid dehydrogenase; Bile acid conjugation; Bile acid transport; Bile acids; Glucocorticoids

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; BILE ACID; CHOLESTEROL 7ALPHA MONOOXYGENASE; CORTICOSTERONE; FATTY ACID TRANSPORTER; FATTY ACID TRANSPORTER 5; GLUCOCORTICOID RECEPTOR; MESSENGER RNA; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER B; ORGANIC SOLUTE TRANSPORTER BETA; SODIUM BILE ACID COTRANSPORTER; UNCLASSIFIED DRUG;

11BETA HYDROXYSTEROID DEHYDROGENASE 1 DEFICIENCY; AKR1D1 GENE; AMIDATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAAT GENE; BILE ACID BLOOD LEVEL; BILE ACID HOMEOSTASIS; CONTROLLED STUDY; CYP7A1 GENE; DNA MODIFICATION; DOWN REGULATION; ENDOPLASMIC RETICULUM; ENZYME DEFICIENCY; FATP2 GENE; FATP5 GENE; GENE; GENE EXPRESSION; GENE TARGETING; GENETIC ANALYSIS; GENOTYPE; HOMEOSTASIS; KNOCKOUT MOUSE; LIVER; LIVER MEMBRANE; MOUSE; NONHUMAN; OATP1A1 GENE; OATP1B2 GENE; OSTB GENE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SHP GENE; SRD5A1 GENE; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; VLCSH2 GENE; WESTERN BLOTTING;

MUS;

EID: 84904309908     PISSN: 22128778     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmet.2014.04.008     Document Type: Article

References (60)

1. Hofmann A.F. The continuing importance of bile acids in liver and intestinal disease. Archives of Internal Medicine 1999, 159:2647-2658.
2. Pols T.W., Noriega L.G., Nomura M., Auwerx J., Schoonjans K. The bile acid membrane receptor TGR5 as an emerging target in metabolism and inflammation. Journal of Hepatology 2011, 54:1263-1272.
3. Watanabe M., Houten S.M., Mataki C., Christoffolete M.A., Kim B.W., Sato H., et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 2006, 439:484-489.
4. Thomas C., Gioiello A., Noriega L., Strehle A., Oury J., Rizzo G., et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metabolism 2009, 10:167-177.
5. Eloranta J.J., Kullak-Ublick G.A. Coordinate transcriptional regulation of bile acid homeostasis and drug metabolism. Archives of Biochemistry and Biophysics 2005, 433:397-412.
6. Pircher P.C., Kitto J.L., Petrowski M.L., Tangirala R.K., Bischoff E.D., Schulman I.G., et al. Farnesoid X receptor regulates bile acid-amino acid conjugation. Journal of Biological Chemistry 2003, 278:27703-27711.
7. Goodwin B., Jones S.A., Price R.R., Watson M.A., McKee D.D., Moore L.B., et al. Aregulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Molecular Cell 2000, 6:517-526.
8. +-taurocholate cotransporting polypeptide gene is activated by glucocorticoid receptor and peroxisome proliferator-activated receptor-γ coactivator-1α, and suppressed by bile acids via a small heterodimer partner-dependent mechanism. Molecular Endocrinology 2006, 20:65-79.
9. Rose A.J., Díaz M.B., Reimann A., Klement J., Walcher T., Krones-Herzig A., et al. Molecular control of systemic bile acid homeostasis by the liver glucocorticoid receptor. Cell Metabolism 2011, 14:123-130.
10. Lu Y., Zhang Z., Xiong X., Wang X., Li J., Shi G., et al. Glucocorticoids promote hepatic cholestasis in mice by inhibiting the transcriptional activity of the farnesoid X receptor. Gastroenterology 2012, 143. 1630-1640.e8.
11. Jung D., Fantin A.C., Scheurer U., Fried M., Kullak-Ublick G.A. Human ileal bile acid transporter gene ASBT (SLC10A2) is transactivated by the glucocorticoid receptor. Gut 2004, 53:78-84.
12. Claudel T., Zollner G., Wagner M., Trauner M. Role of nuclear receptors for bile acid metabolism, bile secretion, cholestasis, and gallstone disease. Biochimica et Biophysica Acta 2011, 1812:867-878.
13. Hagenbuch B., Scharschmidt B.F., Meier P.J. Effect of antisense oligonucleotides on the expression of hepatocellular bile acid and organic anion uptake systems in Xenopus laevis oocytes. Biochemical Journal 1996, 316:901-904.
14. Tomlinson J.W., Walker E.A., Bujalska I.J., Draper N., Lavery G.G., Cooper M.S., et al. 11beta-Hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocrine Reviews 2004, 25:831-866.
15. Odermatt A., Kratschmar D.V. Tissue-specific modulation of mineralocorticoid receptor function by 11beta-hydroxysteroid dehydrogenases: an overview. Molecular and Cellular Endocrinology 2012, 350:168-186.
16. Schweizer R.A.S., Zürcher M., Balazs Z., Dick B., Odermatt A. Rapid hepatic metabolism of 7-ketocholesterol by 11β-hydroxysteroid dehydrogenase type 1. Journal of Biological Chemistry 2004, 279:18415-18424.
17. Mitić T., Shave S., Semjonous N., McNae I., Cobice D.F., Lavery G.G., et al. 11β-Hydroxysteroid dehydrogenase type 1 contributes to the balance between 7-keto- and 7-hydroxy-oxysterols invivo. Biochemical Pharmacology 2013, 86:146-153.
18. Odermatt A., Da Cunha T., Penno C.A., Chandsawangbhuwana C., Reichert C., Wolf A., et al. Hepatic reduction of the secondary bile acid 7-oxolithocholic acid is mediated by 11beta-hydroxysteroid dehydrogenase 1. Biochemical Journal 2011, 436:621-629.
19. Penno C.A., Morgan S.A., Vuorinen A., Schuster D., Lavery G.G., Odermatt A. Impaired oxidoreduction by 11beta-hydroxysteroid dehydrogenase 1 results in the accumulation of 7-oxolithocholic acid. Journal of Lipid Research 2013, 54:2874-2883.
20. Masuzaki H., Paterson J., Shinyama H., Morton N.M., Mullins J.J., Seckl J.R., et al. Atransgenic model of visceral obesity and the metabolic syndrome. Science 2001, 294:2166-2170.
21. Masuzaki H., Yamamoto H., Kenyon C.J., Elmquist J.K., Morton N.M., Paterson J.M., et al. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. Journal of Clinical Investigation 2003, 112:83-90.
22. Tomlinson J.W., Stewart P.M. Modulation of glucocorticoid action and the treatment of type-2 diabetes. Best Practice & Research Clinical Endocrinology & Metabolism 2007, 21:607-619.
23. Kotelevtsev Y., Holmes M.C., Burchell A., Houston P.M., Schmoll D., Jamieson P., et al. 11β-Hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proceedings of the National Academy of Sciences of the United States of America 1997, 94:14924-14929.
24. Morton N.M., Paterson J.M., Masuzaki H., Holmes M.C., Staels B., Fievet C., et al. Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11β-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes 2004, 53:931-938.
25. Wamil M., Battle J.H., Turban S., Kipari T., Seguret D., de Sousa Peixoto R., et al. Novel fat depot-specific mechanisms underlie resistance to visceral obesity and inflammation in 11β-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes 2011, 60:1158-1167.
26. Morton N.M., Holmes M.C., Fiévet C., Staels B., Tailleux A., Mullins J.J., et al. Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11β-hydroxysteroid dehydrogenase type 1 null mice. Journal of Biological Chemistry 2001, 276:41293-41300.
27. Lavery G.G., Zielinska A.E., Gathercole L.L., Hughes B., Semjonous N., Guest P., et al. Lack of significant metabolic abnormalities in mice with liver-specific disruption of 11β-hydroxysteroid dehydrogenase type 1. Endocrinology 2012, 153:3236-3248.
28. Watanabe M., Houten S.M., Wang L., Moschetta A., Mangelsdorf D.J., Heyman R.A., et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. Journal of Clinical Investigation 2004, 113:1408-1418.
29. Rosenstock J., Banarer S., Fonseca V.A., Inzucchi S.E., Sun W., Yao W., et al. The 11-β-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy. Diabetes Care 2010, 33:1516-1522. for the INCB13739-202 Principal Investigators.
30. Gathercole L.L., Lavery G.G., Morgan S.A., Cooper M.S., Sinclair A.J., Tomlinson J.W., et al. 11beta-Hydroxysteroid dehydrogenase 1: translational and therapeutic aspects. Endocrine Reviews 2013, 34:525-555.
31. Lemke U., Krones-Herzig A., Diaz M.B., Narvekar P., Ziegler A., Vegiopoulos A., et al. The glucocorticoid receptor controls hepatic dyslipidemia through Hes1. Cell Metabolism 2008, 8:212-223.
32. Opherk C., Tronche F., Kellendonk C., Kohlmüller D., Schulze A., Schmid W., et al. Inactivation of the glucocorticoid receptor in hepatocytes leads to fasting hypoglycemia and ameliorates hyperglycemia in streptozotocin-induced diabetes mellitus. Molecular Endocrinology 2004, 18:1346-1353.
33. Penno C.A., Arsenijevic D., Da Cunha T., Kullak-Ublick G.A., Montani J.P., Odermatt A. Quantification of multiple bile acids in uninephrectomized rats using ultra-performance liquid chromatography-tandem mass spectrometry. Analytical Methods 2013, 5:1155-1164.
34. Wang X., Spandidos A., Wang H., Seed B. PrimerBank: a PCR primer database for quantitative gene expression analysis, 2012 update. Nucleic Acids Research 2012, 40:D1144-D1149.
35. Russell D.W. The enzymes, regulation, and genetics of bile acid synthesis. Annual Review of Biochemistry 2003, 72:137-174.
36. Hata S., Wang P., Eftychiou N., Ananthanarayanan M., Batta A., Salen G., et al. Substrate specificities of rat oatp1 and ntcp: implications for hepatic organic anion uptake. American Journal of Physiology - Gastrointestinal and Liver Physiology 2003, 285:G829-G839.
37. Doege H., Grimm D., Falcon A., Tsang B., Storm T.A., Xu H., et al. Silencing of hepatic fatty acid transporter protein 5 invivo reverses diet-induced non-alcoholic fatty liver disease and improves hyperglycemia. Journal of Biological Chemistry 2008, 283:22186-22192.
38. Doege H., Baillie R.A., Ortegon A.M., Tsang B., Wu Q., Punreddy S., et al. Targeted deletion of FATP5 reveals multiple functions in liver metabolism: alterations in hepatic lipid homeostasis. Gastroenterology 2006, 130:1245-1258.
39. Mihalik S.J., Steinberg S.J., Pei Z., Park J., Kim D.G., Heinzer A.K., et al. Participation of two members of the very long-chain acyl-CoA synthetase family in bile acid synthesis and recycling. Journal of Biological Chemistry 2002, 277:24771-24779.
40. Steinberg S.J., Mihalik S.J., Kim D.G., Cuebas D.A., Watkins P.A. The human liver-specific homolog of very long-chain acyl-CoA synthetase is cholate:CoA ligase. Journal of Biological Chemistry 2000, 275:15605-15608.
41. Hubbard B., Doege H., Punreddy S., Wu H., Huang X., Kaushik V.K., et al. Mice deleted for fatty acid transport protein 5 have defective bile acid conjugation and are protected from obesity. Gastroenterology 2006, 130:1259-1269.
42. Chong C.K., Mills P., McClean P., Gissen P., Bruce C., Stahlschmidt J., et al. Bile acid-CoA ligase deficiency - a new inborn error of bile acid metabolism. Journal of Inherited Metabolic Disease 2012, 35:521-530.
43. Zhang M., Chiang J.Y.L. Transcriptional regulation of the human sterol 12α-hydroxylase gene (CYP8B1): roles of hepatocyte nuclear factor 4α in mediating bile acid repression. Journal of Biological Chemistry 2001, 276:41690-41699.
44. Brendel C., Schoonjans K., Botrugno O.A., Treuter E., Auwerx J. The small heterodimer partner interacts with the liver X receptor α and represses its transcriptional activity. Molecular Endocrinology 2002, 16:2065-2076.
45. Båvner A., Sanyal S., Gustafsson J.-Å., Treuter E. Transcriptional corepression by SHP: molecular mechanisms and physiological consequences. Trends in Endocrinology & Metabolism 2005, 16:478-488.
46. Csanaky I.L., Lu H., Zhang Y., Ogura K., Choudhuri S., Klaassen C.D. Organic anion-transporting polypeptide 1b2 (Oatp1b2) is important for the hepatic uptake of unconjugated bile acids: studies in Oatp1b2-null mice. Hepatology 2011, 53:272-281.
47. Ballatori N., Christian W.V., Lee J.Y., Dawson P.A., Soroka C.J., Boyer J.L., et al. OSTα-OSTβ: a major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epithelia. Hepatology 2005, 42:1270-1279.
48. Dawson P.A., Haywood J., Craddock A.L., Wilson M., Tietjen M., Kluckman K., et al. Targeted deletion of the ileal bile acid transporter eliminates enterohepatic cycling of bile acids in mice. Journal of Biological Chemistry 2003, 278:33920-33927.
49. Li N., Cui Z., Fang F., Lee J.Y., Ballatori N. Heterodimerization, trafficking and membrane topology of the two proteins, Ostα and Ostβ, that constitute the organic solute and steroid transporter. Biochemical Journal 2007, 407:363-372.
50. Sun A.-Q., Balasubramaniyan N., Xu K., Liu C.J., Ponamgi V.M., Liu H., et al. Protein-protein interactions and membrane localization of the human organic solute transporter. American Journal of Physiology - Gastrointestinal and Liver Physiology 2007, 292:G1586-G1593.
51. Soroka C., Xu S., Mennone A., Lam P., Boyer J. N-Glycosylation of the alpha subunit does not influence trafficking or functional activity of the human organic solute transporter alpha/beta. BMC Cell Biology 2008, 9:57.
52. Boyer J.L., Trauner M., Mennone A., Soroka C.J., Cai S.Y., Moustafa T., et al. Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTα-OSTβ in cholestasis in humans and rodents. American Journal of Physiology - Gastrointestinal and Liver Physiology 2006, 290:G1124-G1130.
53. Dawson P.A., Hubbert M.L., Rao A. Getting the mOST from OST: role of organic solute transporter, OSTα-OSTβ, in bile acid and steroid metabolism. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 2010, 1801:994-1004.
54. Zhang Y., Csanaky I.L., Lehman-McKeeman L.D., Klaassen C.D. Loss of organic anion transporting polypeptide 1a1 increases deoxycholic acid absorption in mice by increasing intestinal permeability. Toxicological Sciences 2011, 124:251-260.
55. Savouret J.F., Antenos M., Quesne M., Xu J., Milgrom E., Casper R.F. 7-ketocholesterol is an endogenous modulator for the arylhydrocarbon receptor. Journal of Biological Chemistry 2001, 276:3054-3059.
56. Makishima M., Lu T.T., Xie W., Whitfield G.K., Domoto H., Evans R.M., et al. Vitamin D receptor as an intestinal bile acid sensor. Science 2002, 296:1313-1316.
57. Paterson J.M., Morton N.M., Fievet C., Kenyon C.J., Holmes M.C., Staels B., et al. Metabolic syndrome without obesity: hepatic overexpression of 11β-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:7088-7093.
58. Anderson C.M., Stahl A. SLC27 fatty acid transport proteins. Molecular Aspects of Medicine 2013, 34:516-528.
59. Shah S., Hermanowski-Vosatka A., Gibson K., Ruck R.A., Jia G., Zhang J., et al. Efficacy and safety of the selective 11β-HSD-1 inhibitors MK-0736 and MK-0916 in overweight and obese patients with hypertension. Journal of the American Society of Hypertension 2011, 5:166-176.
60. Pols T.W.H., Nomura M., Harach T., Lo Sasso G., Oosterveer M.H., Thomas C., et al. TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. Cell Metabolism 2011, 14:747-757.